针对淋病奈瑟菌的耐药指导治疗
耐抗菌药物的淋病奈瑟菌感染对公共卫生构成威胁。本文强调为环丙沙星、头孢克肟和头孢曲松开发三种耐药指导检测方法的工作,讨论当前认识现状与持续挑战,并提出未来方向。
要点
- 环丙沙星耐药由旋转酶A基因第91位密码子单突变决定,已有商业化分子检测指导治疗。
- 头孢克肟耐药由嵌合penA基因或非嵌合区特定位点的6个关键突变之一导致。
- 头孢曲松耐药由penA、ponA、penB和mtr中1个基因突变导致,但预测减敏能力因地区而异。
核心结论
- 本文强调为环丙沙星、头孢克肟和头孢曲松开发三种耐药指导检测方法的工作,讨论当前认识现状与持续挑战,并提出未来方向。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 环丙沙星耐药由旋转酶A基因第91位密码子单突变决定,已有商业化分子检测指导治疗。
- 头孢克肟耐药由嵌合penA基因或非嵌合区特定位点的6个关键突变之一导致。
- 头孢曲松耐药由penA、ponA、penB和mtr中1个基因突变导致,但基于这些基因预测减敏的能力因地理区域而异。
关键数值与推荐
- 原文未报告指南或共识推荐条款。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial-resistant Neisseria gonorrhoeae infections are a threat to public health. Novel strategies for combating such resistance include the development of molecular assays to facilitate real-time prediction of antimicrobial susceptibility. Resistance to ciprofloxacin is determined by the presence of a single mutation at codon 91 of the gyrase A gene; molecular assays to guide therapy are commercially available. Resistance to cefixime is conferred via 1 of 6 critical mutations in either the mosaic penA gene or specific loci in the nonmosaic region. Resistance to ceftriaxone is conferred through mutations in 1 of 4 genes: penA, ponA, penB, and mtr; however, the ability to predict reduced susceptibility based on those genes varies by geographic region. Here, we highlight the work done toward the development of 3 such assays for ciprofloxacin, cefixime, and ceftriaxone, discuss the status of our current understanding and ongoing challenges, and suggest future directions.
引用
- Allan-Blitz LT, Adamson PC, Klausner JD, et al. Resistance-Guided Therapy for Neisseria gonorrhoeae. Clin Infect Dis. 2022. PMID: 35818315. doi:10.1093/cid/ciac371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。